Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into the third and final
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into day 2 of the oncolo
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting begins at 8am (ET).
Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt
